Clavamox is a potentiated penicillin approved for veterinary use in dogs and cats. It combines the broad-spectrum antibiotic activity of amoxicillin with the unique β-lactamase-inhibiting effect of clavulanate potassium for antimicrobial activity. In addition, it provides activity against many Gram-positive and Gram-negative aerobic and anaerobic bacteria. 
 
Clavamox is orally administered – and available in chewable form – to effectively treat skin infections in dogs and cats, periodontal infections in dogs, and urinary tract infections in cats.
 
Each 62.5-mg tablet contains amoxicillin trihydrate equivalent to 50 mg of amoxicillin activity and 12.5 mg of clavulanic acid as the potassium salt. For use in dogs and cats. 
Each 125-mg tablet contains amoxicillin trihydrate equivalent to 100 mg of amoxicillin activity and 25 mg of clavulanic acid as the potassium salt. For use in dogs only. 
Each 250-mg tablet contains amoxicillin trihydrate equivalent to 200 mg of amoxicillin activity and 50 mg of clavulanic acid as the potassium salt. For use in dogs only. 
Each 375-mg tablet contains amoxicillin trihydrate equivalent to 300 mg of amoxicillin activity and 75 mg of clavulanic acid as the potassium salt. For use in dogs only.